Best in Biotech 19 Aug 2025 10 biotech companies you should know about in Spain …of antibody-drug conjugates (ADCs) that “exploit the molecular underpinnings” of advanced cancer. The company’s lead candidate is called ONA-255, which is a first-in-class ADC that is being developed to treat… August 19, 2025 - 16 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 10 Aug 2022 Captor Therapeutics names lead candidate in fight against hepatocellular carcinoma …of the lead drug candidate, Captor has initiated large scale synthesis with a reputable Contract Development and Manufacturing Organization. The CDMO will produce sufficient amounts of drug candidate to complete… August 10, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
Best in Biotech 23 May 2025 Finland: Pushing biotech forward in the land of a thousand lakes …the country’s landscape. Here are nine biotech companies pushing the industry forward in Finland. Table of contents Aplagon Foundation: 2009 Lead candidate: APAC Recent news: Secured a €7 million funding… May 23, 2025 - 10 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
In Depth 24 Jul 2024 Danuglipron: Is Pfizer’s oral weight loss pill a contender in the obesity market? …advance the development of this candidate. This comes after the clinical evaluation of several modified-release once-daily formulations of danuglipron resulted in “encouraging pharmacokinetic data” for several candidates, with one showing… July 24, 2024 - 10 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 18 Feb 2025 T cell engagers: A promising, fast-growing field for cancer and autoimmune disease treatments …lurking? At present, there are a number of T cell engagers in the clinic. California-based Janux Therapeutics has two candidates in phase 1 trials. Its lead candidate JANX007 is designed… February 18, 2025 - 10 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Best in Biotech 7 Oct 2025 Six companies leading the mRNA revolution in biotechnology …mRNA pipeline centered around treating cancer, infectious diseases, and rare diseases. Two of its infectious disease candidates are in phase 1 trials, namely RV-1730 and RV-1770. The candidate RV-1730 is… October 7, 2025 - 10 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 31 Mar 2020 Swiss Biopharma Launches Second Cancer Antibody Deal with Japanese Pharma Giant …rights to develop and commercialize an immuno-oncology drug candidate for an unspecified indication using Numab’s multi-specific antibody platform, MATCH. Antibody-based therapies are becoming increasingly popular in oncology, with Merck’s approved… March 31, 2020 - 3 minutesmins - By David Kirk Share WhatsApp Twitter Linkedin Email
News and Trends 16 Jan 2017 German Antibody for Cancer Diagnostics catches an Australian Eye …Wilex, in Germany, for the worldwide rights to Redectane, an antibody with diagnostic applications in renal cancer. The antibody, Rencarex (girentuximab), which binds to the CAIX antigen on clear cell… January 16, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 29 Aug 2019 HiFiBiO’s €60M Series C to Fund Cancer and Autoimmune Disease Antibody Drugs …also fuel the expansion of HiFiBiO’s antibody production technology, which is based on screening hundreds of single immune cells at a time for the most effective antibody drug candidate. HiFiBiO… August 29, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
In Depth 30 Apr 2025 The future of NSCLC treatment: what’s in store for the therapeutic space? …candidates in the clinic trying to combat this inadequacy. And some of the candidates could be on their way beyond the clinic, as they are being evaluated in late-stage trials…. April 30, 2025 - 12 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 8 Dec 2025 Top biotech deals in November 2025 …of drug-Fc conjugate (DFC) therapies. Small molecules and peptides are bound to an antibody fragment to make these therapies. Merck will soon get a hold of Cidara’s lead candidate in phase 3 studies, CD388, a small molecule neuraminidase inhibitor… December 8, 2025 - 12 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Best in Biotech 30 Jan 2017 The Shiniest Golden Vertex? 15 Great Biotechs in Cambridge …shown significant advantages over antibody-drug conjugates in preclinical models. Clinical trials for the first candidate are due to start in 2017. Acacia Pharma focuses on conditions caused by aggressive therapies,… January 30, 2017 - 8 minutesmins - By Denise Neves Gameiro Share WhatsApp Twitter Linkedin Email